Lymphoma & Myeloma Chemotherapy Regimens

The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option.  In addition, treatment choices can change over time as more evidence becomes available.Use of these documents is the responsibility of the prescribing clinician and is subject to the HSE.ie terms of use.

NCCP Guidance on riTUXimab rapid infusion rate is available here

Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie.

Lymphoma and Myeloma Chemotherapy Regimens

Regimen Name Indication

ABVD Therapy

Regimen

00290a

Hodgkin’s Lymphoma.

BEAM Autologous Transplant Conditioning Protocol

Regimen

00408a

Autologous conditioning in non-Hodgkins Lymphoma (NHL)

00408b

Autologous conditioning in Hodgkins Lymphoma

Bortezomib and Dexamethasone Therapy

Regimen

00270a

Treatment of adult patients with progressive multiple myeloma who have received at least one prior therapy.

Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy-21 day*

Regimen

00416a

Treatment of newly diagnosed myeloma in adult patients with high risk features.

00416b

Treatment of relapsed or refractory myeloma that has received prior therapy in adult patients with high risk features.

Bortezomib, Thalidomide and Dexamethasone (VTD) Induction Therapy

Regimen

00274a

Bortezomib, thalidomide and dexamethasone for induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

Bortezomib, Melphalan and Prednisolone

Regimen

00275a

Treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

CyBorD/ Cylophosphamide, Bortezomib, and Dexamethasone-21 day Therapy

Regimen

00273a

Treatment of newly diagnosed symptomatic multiple myeloma*

00273b

Treatment of relapsed/refractory multiple myeloma*

Lenalidomide 25mg and Dexamethasone Therapy-28 day

Regimen

00218a

Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.

00218b

Treatment of multiple myeloma in adult patients who have received at least one prior therapy.

Modified CyBord/ Bortezomib/ Cyclophosphamide and Dexamethasone – weekly therapy

Regimen

00299a

Treatment of newly diagnosed symptomatic multiple myeloma.

00299b

Treatment of relapsed/refractory multiple myeloma.

Brentuximab vedotin Monotherapy

Regimen 

Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):

00234a

Following autologous stem cell transplant (ASCT)

or

00234b

Following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option

00234c

Treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)

CHOEP Therapy-21 days

Regimen

00396a

Treatment of T-cell Non-Hodgkins Lymphoma.

Ibrutinib Therapy (Mantle Cell Lymphoma)

Regimen

00297a

As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Idelalisib Monotherapy

Regimen

00291a

Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.

Nivolumab Monotherapy

Regimen

00349d

As monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.

Nordic Therapy Protocol

Regimen

00393a

Mantle Cell Lymphoma.

Pixantrone Therapy

Regimen

00255a

Monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lymphomas (NHL).

The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.

Pomalidomide and Dexamethasone

Regimen

00245a

Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

RiTUXimab and Bendamustine Therapy

Regimen

00345a

Treatment of patients with previously untreated indolent CD20-positive, stage III-IV non-hodgkin lymphoma (NHL).

00345b

Treatment of patients with previously untreated CD20-positive, stage III-IV mantle cell lymphoma (MCL), ineligible for autologous stem cell transplant.

(R*)-CHOP -14 days

Regimen

00409a

Treatment of Non Hodgkins Lymphoma (NHL)*

*Rituximab to be included in CD20 positive patients

(R*)-CHOP -21 days

Regimen

00307a

Treatment of Non Hodgkins Lymphoma (NHL).*

*Rituximab to be included in CD20 positive patients.

(R**)-DHAP Therapy

Regimen

00395a

Treatment of relapsed Non Hodgkin Lymphoma**

**Rituximab to be included in CD20 positive patients

00395b

Treatment of relapsed Hodgkins Lymphoma

 (R**)-ICE ((RiTUXimab), Ifosfamide, Carboplatin and Etoposide) Therapy

Regimen

00397a

Treatment of relapsed/refractory Non Hodgkin’s Lymphoma**

**Rituximab to be included in CD20 positive patients

00397b

Treatment of relapsed/refractory Hodgkin’s Lymphoma

RiTUXimab 375mg/m2 Therapy-Follicular Lymphoma

Regimen

00208a

Maintenance therapy for the treatment of follicular CD20 positive, B-cell NHL patients responding to induction therapy.

00208b

Monotherapy for treatment of patients with stage III-IV follicular CD20 positive, B-cell NHL who are chemoresistant or are in the second or subsequent relapse after chemotherapy.

(*RiTUXimab) Cyclophosphamide and Prednisolone (R*)-CVP ) Therapy-21 days

Regimen

00293a

First line treatment for patients with stage 3/4 follicular lymphoma

00293b

Treatment of patients with relapsed/refractory low grade B cell Non Hodgkin’s lymphoma (NHL)*

*Rituximab to be included in CD20 positive patients.

Siltuximab Monotherapy

Regimen

00277a

Treatment of adult patients with Multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus 8 (HHV-8) negative.